Anti-Gliadin antibody in Psoriasis: A case-control study
Authors
Abstract:
Background and objective: Psoriasis is chronic inflammatory skin disorder with a wide variety of clinical presentations. Presence of anti-gliadin antibody (AGA) has been reported in 16% of psoriatic patients. This study was designed to determine the frequency of the presence of AGA in psoriatic patients. Materials and Methods: After recording the demographic data and the severity of disease according to PASI scoring system, serum of 10 psoriatic patients and 100 healthy controls were studied for the presence of AGA using indirect innumofluorescence method. Results: AGA was present in sera of 4 (3 males and one female) psoriatic patient while all controls were negative. Three patients were from 20 to 40 years of age. All four AGA positive patients suffered from plaque type psoriasis. The disease severity was mild in one, moderate in two, and severe in one patient. None of them suffered from gastrointestinal problems. Conclusion: Although AGA may be present in the serum of some psoriatic cases, a significant relation between skin lesion and hypersensivity to gluten has not been determined yet. More studies using more specific and sensitive assessment methods and larger sample sizes are suggested.
similar resources
Insulin resistance in psoriasis: A case-control study
Background: Recent studies suggest that psoriasis may be a pathogenic factor for the metabolic syndrome and atherosclerosis. The aim of our study was to investigate the metabolic state in psoriatic patients in order to clarify the association between psoriasis and insulin resistance.Methods: This single-centre, case- control study was performed between 2008 and 2010 to evaluate the metabo...
full textprevalence of atopic dermatitis in children with type 1 diabetes mellitus in southeastern of iran (kerman province): a case-control study
چکیده ندارد.
15 صفحه اولPsoriasis and hypertension: a case-control study.
BACKGROUND Several studies stated that patient with psoriasis carried an increased risk of psoriasis but some studies did not demonstrate this association. OBJECTIVES The aim of this study was to evaluate the prevalence of hypertension in psoriasis based on a sample of Spanish population. METHODS This was a hospital-based case-control study involving 661 psoriatic patients (cases) and...
full textComparison of Anti Thyroid Peroxidase Antibody (TPOAb) levels in people with depression and healthy people: case control-study
Background and Aim: Depression is a common psychiatric disorder with a high prevalence in military personnel. Recently, the relationship between depression and some hormones has been reported. In current study, the serum levels of anti-thyroid peroxidase (anti-TPO), triiodothyronine (T3), thyroxin (T4) and thyroid-stimulating hormone (TSH) was assessed in people with depression and compared wit...
full textAtaxia, peripheral neuropathy, and anti-gliadin antibody. Guilt by association?
Some authors contend that patients with idiopathic neurological disease who are also anti-gliadin antibody seropositive are gluten sensitive. However, anti-gliadin antibodies lack disease specificity being found in 10% of healthy blood donors. We report a study comparing anti-gliadin antibody with other food antibodies in patients with idiopathic ataxia (20), hereditary ataxias (seven), or idio...
full textProthrombin Time, an Indicator for Psoriasis Activity: A Case - Control Study
Background: Psoriasis is a common chronic and recurrent inflammatory skin disorder related to the immune system and characterized by the rapid growth of skin cells. To date, no study has been conducted on the role of the prothrombin time index in determining the disease activity and the prognosis of these patients. Recognizing the factors influencing the prognosis of this disease can be helpf...
full textMy Resources
Journal title
volume 8 issue 4
pages 272- 275
publication date 2005-07-01
By following a journal you will be notified via email when a new issue of this journal is published.
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023